You are here

Business

Peak Drama: Valeant's Ex-Goldman CFO Responds, Refuses To Resign From Board, Accuses Valeant Of Smear Campaign

As we wrote first thing this morning, while the fate of Valeant CEO Pearson was largely known (he is now out) and that Ackman will go down with the Valeant ship was largely as expected, what was a complete shock in the copmany's press release was that the decision to throw its former CFO, Howard Schiller who formerly ran Goldman's healthcare group, under the bus and accuse him of cooking the company's books.

Share Buybacks Turn Toxic

Share Buybacks Turn Toxic

By Wolf Richter, WOLF STREET

Companies are still borrowing and spending billions on buying back their own shares – one of the big drivers behind the blistering stock market rally of the past few years. It worked wonderfully and without fail. But suddenly, it’s doing the opposite, and now the shares of the biggest buyback queens are getting hammered. Something broke in the gears of this financially engineered market!

Existing Home Sales Crash Most In 6 Years: NAR Blames Slowing Economy, Bubbly Home Prices

Existing Home Sales Crash Most In 6 Years: NAR Blames Slowing Economy, Bubbly Home Prices

Existing home sales plunged 7.1% MoM in February, massively missing expectations of a 3.0% drop. Absent the regulation-driven drop in November, this is the largest MoM drop since July 2010 as realtors warn that "home prices and rents outpacing wages and anxiety about the health of the economy are holding back a segment of would-be buyers."

 

 

Median prices appear to have ended in an airpocket:

As NAR reports,

Valeant Throws Its Former CFO Under The Bus; Accuses Him Of Cooking The Books After Coming Over From Goldman Sachs

Valeant Throws Its Former CFO Under The Bus; Accuses Him Of Cooking The Books After Coming Over From Goldman Sachs

Back in October, we tried to "tie the Valeant roll-up together: Presenting The Goldman "Missing Link" in which we showed that Howard Schiller, Valeant's CFO from December 2011 to June 2015, previously ran Goldman Sachs’ health-care practice until 2009, when he became the chief operating officer of Goldman’s investment bank. The next year, the bank advised Valeant on its breakout purchase of Biovail Corp.

Pages